CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 446 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $426,235 | -18.2% | 7,892 | -0.3% | 0.32% | -29.1% |
| Q1 2024 | $521,069 | +1.1% | 7,912 | -26.6% | 0.45% | -6.6% |
| Q4 2023 | $515,273 | +40.4% | 10,783 | +10.6% | 0.49% | +24.9% |
| Q3 2023 | $367,068 | -21.2% | 9,747 | -0.8% | 0.39% | -16.2% |
| Q2 2023 | $465,710 | +21.9% | 9,823 | -2.2% | 0.46% | -4.9% |
| Q1 2023 | $382,086 | -15.0% | 10,044 | -23.7% | 0.49% | -21.7% |
| Q4 2022 | $449,256 | -31.7% | 13,166 | +30.8% | 0.62% | -21.8% |
| Q3 2022 | $658,000 | +10.8% | 10,068 | -13.0% | 0.80% | +14.3% |
| Q2 2022 | $594,000 | +15.1% | 11,567 | +35.9% | 0.70% | +63.2% |
| Q1 2022 | $516,000 | -3.4% | 8,511 | +16.4% | 0.43% | -1.8% |
| Q4 2021 | $534,000 | -16.3% | 7,309 | +28.2% | 0.44% | -27.5% |
| Q3 2021 | $638,000 | -17.8% | 5,701 | +19.0% | 0.60% | -21.9% |
| Q2 2021 | $776,000 | +72.4% | 4,791 | +29.6% | 0.77% | +58.4% |
| Q1 2021 | $450,000 | +67.3% | 3,697 | +110.1% | 0.48% | +77.7% |
| Q4 2020 | $269,000 | – | 1,760 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |